New PET scan could reveal early drug response in rare lung disease
NCT ID NCT05467397
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a special PET scan using [11C]acetate can detect early signs that the drug rapamycin is working in people with lymphangioleiomyomatosis (LAM), a rare lung disease. Seven adults with LAM and kidney tumors will get one or two scans over 3–6 months. The goal is to see if the scan can serve as a quick, non-invasive biomarker of treatment response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[11C]acetate (a radioactive tracer used in PET scans)
What this could lead to
If successful, this PET scan could provide a new way to quickly see if rapamycin is working in LAM patients, helping doctors adjust treatment sooner.
What could go wrong
This is a very small, early-phase study with only 7 participants, so results may not apply to everyone. The scan is experimental and not yet proven to be reliable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS COMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States